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Abstract
Background: Higher prevalence of atherosclerosis and higher cardiovascular risk is observed in HIV-infected individuals. The
biological mechanisms underlying these processes are unclear. Several studies have implicated genetic variants in the
inflammatory genes in cardiovascular disease and in HIV natural course infection.
Methods & Findings: In this study we have tested the possible association between genetic variants in several inflammatory
genes and asymptomatic cardiovascular disease measured by carotid intima media thickness (cIMT) and atherosclerotic
plaque presence as dependent variables in 213 HIV-infected individuals. A total of 101 genetic variants in 25 candidate
genes have been genotyped. Results were analyzed using Plink and SPSS statistical packages. We have found several
polymorphisms in the genes ALOX5 (rs2115819 p= 0.009), ALOX5AP (rs9578196 p= 0.007; rs4769873 p= 0.004 and rs9315051
p= 0.0004), CX3CL1 (rs4151117 p= 0.040 and rs614230 p= 0.015) and CCL5 (rs3817655 p= 0.018 and rs2107538 p= 0.018)
associated with atherosclerotic plaque. cIMT mean has been associated with CRP (1130864 p= 0.0003 and rs1800947
p= 0.008), IL1RN (rs380092 p= 0.002) and ALOX5AP (rs3885907 p= 0.02) genetic variants.
Conclusions: In this study we have found modest associations between genetic variants in several inflammatory genes and
atherosclerotic plaque or cIMT. Nevertheless, our study adds evidence to the association between inflammatory pathway
genetic variants and the atherosclerotic disease in HIV-infected individuals.
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Background
Cardiovascular disease (CVD), has been identified as a major
cause of death in HIV-infected people [1–3]. HIV-infected
individuals have accelerated atherogenesis, which is associated to
a high risk of suffering a cardiovascular event such as coronary
artery disease (CAD), peripheral vascular disease and stroke. The
prevalence of these events in HIV-infected subjects is higher than
in the general population and has an earlier onset [4–6]. The
biological mechanisms underlying such risk among HIV-infected
people are unclear [7].
Several studies implicate inflammation processes in CVD [7–
10]. Non-HIV infected cohort studies have demonstrated that
markers of inflammation are strongly predictive of CVD events
and mortality [8]. Inflammatory markers are elevated in HIV-
infected patients in comparison with non-infected individuals
[7,11]. It has been hypothesized that this increased inflammation
may be the explanation for the elevated cardiovascular risk in
HIV-infected individuals [9].
Mechanisms of immune activation and inflammation have been
proposed as the cause of earlier CAD in HIV [7]. HIV is thought
to play a crucial role in the pathogenesis of atherosclerosis in HIV-
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infection [6,11]. In addition to the high prevalence of traditional
CVD risk factors in HIV-infected individuals, several factors such
as immunosupression, inflammation, HIV ability to induce foam
cell transformation, cumulative exposure to antiretroviral drugs,
and mitochondrial and metabolic dysfunctions have been hypoth-
esized to be involved in HIV associated atherosclerosis [11–13].
Studies on the inflammatory pathways have found genetic
variants associated with atherosclerosis and cardiovascular risk in
the general population [10]. Inflammatory marker genes such as
C-Reactive Protein (CRP) [14,15], Interleucin-6 (IL6) [10],
Interleucin-1 (IL1) gene cluster [16,17], Interleucin-18 (IL18)
[10], Interleucin-8 (IL8) [10], Tumor Necrosis Factor (TNF) [10],
Lymphotoxin-a (LTA) [10], Fractalkine Receptor (CX3CR1)
[18,19], Chemokine Receptor 5 (CCR5) [20], Chemokine Receptor
2 (CCR2) and the 5-lipoxygenase (5-LO) pathway genes [10,21]
have been associated with cardiovascular events. Regarding HIV-
infected patients, the most important investigation is a Genome
Wide Association Study (GWAs) conducted by Shrestha et al. [22]
that related two variants in the gene Ryanodine Receptor 3 (RYR3)
with greater carotid Intima Media Thickness (cIMT), a surrogate
marker of atherosclerosis. This finding has been replicated by the
same authors in a later study [23], but there is no independent
study confirming this result.
The immunological and inflammatory pathways have many
shared genes that may interact in the pathogenesis of atheroscle-
rosis in HIV-infected individuals. The aim of this study was to
assess the implication of genetic variants in relevant inflammatory
genes in the atherosclerotic disease of HIV infected subjects.
Materials and Methods
Study population
We performed a cross-sectional study with 213 Spanish
Caucasians HIV-infected individuals attended in Hospital Uni-
versitari Mu´tuaTerrassa (Terrassa, Catalonia, Spain). This project
was approved by the local ethics committee (Comite´ e´tico de
Investigacio´n Clı´nica del Hospital Universitario Mu´tuaTerrassa -
Approval number: EO/0915). All Participants gave written
informed consent for genetic testing. At the time of enrolment,
demographic, clinical and biochemical variables were collected
from each patient by interviews and from medical notes.
Simultaneously ultrasonographic measures (cIMT and atheroscle-
rotic plaque presence) were performed.
Carotid artery Ultrasound
Carotid Intima Media Thickness (cIMT) is the most widely used
surrogate marker of atherosclerosis. It relies on the fact that the
Table 1. Genotyped SNPs.
Chromosome Gene Genotyped SNPs
1 CRP rs1205; rs1130864; rs1800947
2 IL1B rs55778004; rs1143634; rs1143633; rs1143627*; rs16944*
IL1RN rs3087263; rs380092; rs431726; rs452204; rs4252019; rs315952; rs4252041
3 CCR2 rs3762823; rs1799864
CCR5 rs333*
IL12A rs2243123; rs583911
4 IL8 rs4073*; rs2227306
CXCL1 rs4074
CXCL2 rs9131; rs3806792*
CXCL10 rs8878; rs11548618*
IL2 rs2069778; 2069777
6 LTA rs1800683; rs2239704; rs909253; rs2229094; rs2229092
TNF rs4248160*; rs3093662
7 IL6 rs1800795; rs2069833; 2069840; rs1554606
9 IL33 rs4742170; rs7019575; rs7037276; rs1412420; rs7047921; rs1332290
10 CXCL12 rs1801157; rs2236533; rs2236534; rs2839693; rs10793538; rs3780891; rs7092453
ALOX5 rs12783095; rs3824612; rs934187; rs7918542; rs7099684; rs2115819; rs10900213; rs11239523; rs12264801;
rs1565096; rs1487562; rs3780914
11 IL18 rs3882891; rs5744258; rs5744247; rs795467; rs2043055
13 ALOX5AP rs9579645; rs9579646; rs4075131; rs9578196; rs4293222; rs12429692; rs4769873; rs9315045; rs4503649; rs3885907;
rs10162089; rs4254165; rs17245204; rs9579648; rs10507393; rs9315048; rs9315051; rs3935644; rs4769060
15 RYR3 rs2229116*
16 CX3CL1 rs170364; rs170361; rs4151117; rs614230
17 CCL2 rs1024611; rs3760396
CCL5 rs3817655; rs2280789; rs2107538
CCL3 rs1719134
CCL4 rs1719147
*Selected from previous published studies.
doi:10.1371/journal.pone.0112279.t001
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Table 2. Baseline characteristics of sample population.
Variable Value Atherosclerotic Plaque Presence
Yes (n = 83) No (n = 130)
Age, years6sd 45.3468.20 49.6768.38 42.5866.79
Males, n (%) 166 (77.9) 61 (73.5) 105 (80.8)
Body Mass Index*, Kg/m26sd 24.0863.76 24.1164.09 24.0663.56
Abdominal Obesity{, n (%) 26 (12.2) 15 (18.3) 11 (8.6)
Metabolic Syndrome`, n (%) 16 (7.5) 10 (12.5) 6 (4.7)
Hypertension1, n (%) 20 (9.4) 14 (17.7) 6 (4.7)
Diabetes Mellitus||, n (%) 8 (3.8) 7 (8.4) 1 (0.8)
Dyslipidemia#, n (%) 59 (27.7) 28 (35.0) 31 (24.0)
Atherosclerosis Characteristics
cIMT mean, mm6sd 0.8960.21 1.0160.21 0.8160.17
Plaque presence, n (%) 83 (39.0) 83 (100) 0 (0)
Smoking Habits
Smokers, n (%) 150 (70.4) 61 (74.4) 89 (70.1)
Non Smokers, n (%) 59 (27.7) 21 (25.6) 38 (29.9)
Lipid profile
Total Cholesterol, mg/dl6sd 181.41643.13 193.01647.70 174.01638.33
LDL Cholesterol, mg/dl6sd 111.70649.15 118.81649.23 107.15648.75
HDL Cholesterol, mg/dl6sd 46.97616.17 47.98616.24 46.32616.16
Non-HDL Cholesterol, mg/dl6sd 134.67642.28 145.03648.16 128.05636.75
Triglycerides, mg/dl6sd 148.09692.78 160.76684.70 140.00697.04
HIV Characteristics
Time Infected, years6sd 11.9767.62 13.2667.50 11.1067.62
Hepatitis C Coinfection, n (%) 102 (47.9) 45 (54.9) 57 (44.5)
Antiretroviral Therapy**, n (%) 175 (82.2) 72 (87.8) 103 (80.5)
PIs, n(%) 62 (29.1) 24 (30.0) 38 (30.4)
nRTIs, n(%) 166 (77.9) 69 (86.2) 97 (77.0)
NNRTIs, n(%) 101 (47.7) 42 (52.5) 59 (46.8)
Entry Inhibitors, n(%) 2 (0.9) 1 (1.2) 1 (0.8)
Integrase Inhibitors, n(%) 12 (5.6) 7 (8.8) 5 (4.0)
Previous Antiretroviral Therapies, n (%) 167 (78.4) 68 (82.9) 99 (77.3)
CD4+ cell count, cells/ml6sd 581.256339.53 610.106359.48 562.836326.23
CD4+ nadir cell count, cells/ml6sd 301.746222.79 310.096242.74 296.396209.88
Viral Load. 19 copies/ml, n (%) 71 (33.3) 23 (27.7) 48 (36.9)
Viral Load, copies/ml (95%IQR) 95759.656203731.45 14352.03661553.87 43494.406152702.15
CDC Stage
A, n (%) 143 (67.1) 59 (72.8) 84 (67.2)
B, n (%) 13 (6.1) 3 (3.7) 10 (8.0)
C, n (%) 50 (23.5) 19 (23.5) 31 (24.8)
Diagnosed AIDS, n (%) 92 (43.2) 37 (45.1) 55 (44.0)
Risk Group
Drug Users, n (%) 78 (36.6) 35 (50.7) 43 (40.6)
Sexual Transmission, n (%) 91 (42.7) 32 (46.4) 59 (55.7)
Others, n (%) 6 (2.8) 2 (2.9) 4 (3.8)
*Body Mass Index (BMI): the individual’s body mass divided by the square of their height.
{Abdominal Obesity: waist circumference.102 cm in men and.88 cm in women.
`Metabolic Syndrome was defined as having two or more of the following characteristics: Diabetes Mellitus||; Blood Pressure $140/90 mmHg; Dyslipidemia#;
Abdominal Obesity{ and hypertension1.
1Hypertension was: systolic blood pressure $140 and/or diastolic blood pressure $90 mmHg and/or antihypertensive treatment.
||Diabetes Mellitus: fasting glucose levels $126 mg/dl, and/or having diabetes symptoms and glucose levels $200 mg/dl in a random determination and/or diabetes
treatment.
#Dyslipidemia: Total Cholesterol $240 mg/dl, and/or HDL Cholesterol #35 mg/dl, and/or Triglycerides $200 mg/dl and/or lipid lowering drugs
HIV and Atherosclerosis: Candidate Gene Study
PLOS ONE | www.plosone.org 3 November 2014 | Volume 9 | Issue 11 | e112279
presence of atherosclerosis in one vascular bed will correlate with
the atherosclerosis in another vascular bed. High-resolution B-
mode ultrasound of the carotid arteries has been well validated in
the non infected population as a surrogate marker of cardiovas-
cular risk [24].
cIMT measurements and atherosclerotic plaque presence were
obtained for each patient using a B-mode ultrasound recording
with a 7 to 14-MZ transductor. For the imaging studies, patients
were placed in the supine position with their head in the midline
position and tilted slightly upwards, and the heart in systole. For
each participant, a total of eight measures were obtained: left and
right carotid primitive and bulb region in both proximal and distal
walls. The cIMT value was defined as the mean of all values
excluding those corresponding to atherosclerotic plaque thickness.
According to Manheim cIMT consensus, atherosclerotic plaque
presence is defined as a focal structure encroaching into the
arterial lumen by at least 0.5 mm or 50% of the surrounding IMT
value [25]. It was recorded as a bimodal variable (yes/no). All
measures were performed by the same operator with an
experimental intra-variability of 4.7%.
Genotyping
Genomic DNA was extracted from whole blood using the
QIAamp DNA Blood Mini kit (Qiagen, Izasa, Barcelona, Spain)
following the manufacturer’s instructions. Genotyping was per-
formed using Competitive Allele PCR methodology (KBioscience,
Hoddesdon, United Kingdom). Genes from the inflammatory
pathway were selected. A total of 101 genetic variants or single
nucleotide polymorphisms (SNPs) in 25 candidate genes were
tested (Table 1). TagSNPs were selected from HapMap for
maximum coverage of the genes (Selection criteria: R2.0.8 and
minor allele frequency (maf).0.05). We also included some
relevant SNPs from other studies in HIV and non-HIV infected
populations.
Statistical analysis and quality control
Statistical analyses were performed using the G*Power Calcu-
lator [26], SPSS 20 (SPSS, Chicago, IL) and Plink 1.07 [27]
statistical packages. The study had an 80% power (considering
a= 0.05 and b= 0.95, two-sided) to capture the effect of SNPs
with maf$0.1 and Odds ratio (OR)$2. For rarer alleles (maf,
0.1), the study had a 75% power to capture genetic effects with
OR$3. For continuous variables the study had a 95% power
(considering a= 0.05 and b= 0.95, two-sided) to capture the effect
of SNPs with maf$0.1.
Genotype call rate, Hardy-Weinberg equilibrium (HWE) and
maf was assessed for each SNP using Plink 1.07. Those SNPs with
call rates,95% or maf,0.01 and individuals with more than 5%
missing genotypes were excluded from the analyses.
Chi square analyses or fisher exact tests (for those alleles with
less than 5 counts in any group) were used to investigate the
possible association of atherosclerotic plaque with genetic variants.
cIMT variable was recorded as a continuous variable and it was
normally distributed. Linear regression analyses were used to
compare cIMT values with gene alleles.
Age, abdominal obesity, metabolic syndrome, hypertension,
diabetes, total cholesterol, non-HDL cholesterol, LDL cholesterol
and triglycerides were significantly associated with atherosclerotic
plaque presence (p,0.05 in all cases). Age, hypertension, diabetes,
dyslipidemia, total cholesterol, non-HDL cholesterol and LDL
cholesterol were significantly associated with cIMT (p,0.05 in all
cases).
Lipid values were highly correlated (correlation coefficient.
0.75 in all cases). Only dyslipidemia was included as a clinical
adjusting variable in the regression models. Metabolic syndrome
was collinear with the variables diabetes, dyslipidemia, abdominal
obesity and hypertension. Metabolic syndrome was not included
as a clinical variable in the regression model for atherosclerotic
plaque presence.
For atherosclerotic plaque presence, age, abdominal obesity,
hypertension, diabetes and dyslipidemia were included in logistic
regression analyses as adjusting clinical variables for all the
findings. For cIMT, age, hypertension, diabetes, and dyslipidemia
were included in the regression analyses as adjusting clinical
variables for all the findings. For the importance of HAART in the
vascular pathogenesis, it was included in both adjustments.
Results
Study Population
Demographic, lipid profile and HIV baseline characteristics of
the study population are shown in Table 2. Mean age was 45.34
(SD68.20) years. Males constituted 77.9% of the samples. 82.2%
of the individuals were receiving Highly Active Antiretoviral
Therapy (HAART) at the time of the study. Atherosclerotic plaque
presence (indicator of atherosclerotic lesion [28]) and cIMT means
(indicator of arterial remodelling [29]) were the dependent
variables investigated as markers of CVD. The study population
was classified in two groups according to the bimodal variable
atherosclerotic plaque presence. Baseline characteristics are shown
in Table 1. Patients with atherosclerotic plaque presence con-
formed 39% of the cohort (n = 83), with 73.5% males and a mean
age of 49.67 (SD68.38) years. Patients without atherosclerotic
plaque had a mean age of 42.58 (SD66.79) years and 80.8% were
males.
Quality Control
Hardy-Weinberg Equilibrium. All SNPs were in HWE
except for IL1B rs16944 (p= 0.044), IL1RN rs380092 (p= 0.006),
CXCL12 rs2236533 and rs2236533 (p= 0.040 and p= 0.029
respectively) and ALOX5 rs3824612 (p= 0.025).
SNP Quality control. Three of the genotyped SNPs were
excluded from the analysis, because of a call rate,95% (IL1RN
rs3087263, CX3CR1 rs2669845 and IL6 rs2069833) and two
because of a maf,0.01 (CXCL10 rs11548618 and TNF
rs4248160). Two SNPs (IL1B rs55778004 and IL1RN
rs4252019) were monomorphic in our population. The remaining
94 SNPs were included in the analysis.
Single Marker Analysis
Atherosclerotic Plaque Presence Analysis. Single marker
analyses by Chi-square revealed 12 associations with atheroscle-
rotic plaque presence (Table 3). IL1RN rs4252041 rare allele was
associated with atherosclerotic plaque presence (p= 0.027,
OR = 2.40). CXCL2 rs9131 and rs3806792 rare alleles were
associated with atherosclerotic plaque absence (p= 0.035,
OR = 0.65 and p= 0.026, OR = 0.63 respectively) whereas
ALOX5 rs2115819 was associated with atherosclerotic plaque
presence (p= 0.008, OR = 1.73). Three ALOX5AP SNPs were
associated with atherosclerotic plaque absence: rs9578196
**Antiretroviral Therapy: PIs (Protease Inhibitors); nRTIs (Nucleoside Reverse Transcriptase Inhibitors); NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors); Entry
Inhibitors and Integrase Inhibitors.
doi:10.1371/journal.pone.0112279.t002
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(p= 0.014, OR = 0.45); rs4769873 (p= 0.011, OR = 0.40) and
rs9315051 (p= 0.001, OR = 0.27).
CX3CL1 rs170361, rs4151117 and rs614230 were associated
with atherosclerotic plaque absence (p= 0.040, OR = 0.57;
p= 0.024, OR = 0.55 and p= 0.013, OR = 0.59 respectively).
Finally, two CCL5 SNPs were associated with atherosclerotic
plaque presence: rs3817655 (p= 0.035, OR = 1.72) and rs2107538
(p= 0.033, OR = 1.71).
Single marker analyses by logistic regression using age,
abdominal obesity, hypertension, diabetes, dyslipidemia and
HAART as adjusting clinical variables showed 8 positive
associations.
ALOX5 rs2115819 rare allele C was associated with athero-
sclerotic plaque presence (p= 0.009, b= 2.03). Three ALOX5AP
SNPs were associated with atherosclerotic plaque absence:
rs9578196 (p= 0.007, b= 0.33); rs4769873 (p= 0.004, b= 0.25);
and rs9315051 (p= 0.0004, b= 0.15).
CX3CL1 rs4151117-G and rs614230-C were associated with
atherosclerotic plaque absence (p= 0.040, b= 0.52 and p= 0.015,
b= 0.54 respectively). Two CCL5 SNPs were associated with
atherosclerotic plaque presence: rs3817655 (p= 0.018, b= 1.96)
and rs2107538 (p= 0.018, b= 1.93).
Carotid Intima Media Thickness Analysis. Single marker
analysis by linear regression showed 6 associations with cIMT.
(Table 4). CRP rs1130864 was associated with smaller cIMT
values (p= 0.006, b=20.06) whereas rs1800947 was associated
with greater cIMT (p= 0.028, b= 0.09). IL1RN rs380092 was not
in HWE, but we found it associated with smaller cIMT (p= 0.019,
b=20.06). IL8 rs2043055 and ALOX5AP rs3885907 showed
association with greater cIMT (p= 0.040, b= 0.04 and p= 0.030,
b= 0.05 respectively). Finally, CX3CL1 rs170361 showed a trend
towards association with smaller cIMT (p= 0.049, b=20.05).
Single marker analyses by linear regression using age, hyper-
tension, diabetes mellitus, dyslipidemia and HAART as adjusting
clinical variables showed 4 significant associations. Two CRP
SNPs showed association with cIMT: rs1130864 with smaller
cIMT (p= 0.0003, b= -0.07) and rs1800947 with greater cIMT
(p= 0.008, b= 0.10). IL1RN rs380092 rare allele T was associated
with smaller cIMT (p= 0.002, b=20.07). Finally ALOX5AP
rs3885907 allele C was associated with greater cIMT (p= 0.02,
b= 0.05).
Discussion
In this study we have tested the possible association between
genetic variants in several inflammatory genes and CVD measured
by cIMT and atherosclerotic plaque presence in 213 HIV-infected
individuals. We have found several polymorphisms in the ALOX5,
ALOX5AP, CX3CL1 and CCL5 genes significantly associated
with atherosclerotic plaque, whereas cIMT mean has been
associated with CRP, IL1RN and ALOX5AP genetic variants.
Atherosclerotic Plaque
The ALOX5 rs2115819-C allele was associated with athero-
sclerotic plaque presence and the ALOX5AP rs9578196-T,
rs4769873-T and rs9315051-G alleles with atherosclerotic plaque
absence. Genetic variants in ALOX5 and ALOX5AP have been
previously linked to CVD in non-HIV infected populations [21].
These two genes encode for two important proteins of the 5-LO
pathway which has been previously linked to atherosclerosis [21].
Knock-out mice of ALOX5 showed less atherosclerotic plaque
formation [21]. Studies in HIV-infected cultured cells have shown
a diminished function of 5-LO pathway due to gp120 HIV-protein
presence [30,31]. Our results, showing that ALOX5 and
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ALOX5AP may influence CVD in HIV patients, contribute to the
growing evidence on the relevance of these genes on CVD.
The CX3CL1 rs614230-C allele was found associated with
absence of atherosclerotic plaque. This allele has been previously
associated with smaller cIMT in a German non-HIV infected
subjects (CAPS cohort) although this finding was not replicated in
a French cohort (3C cohort) [18]. To our knowledge, the
association found between CX3CL1 rs4151117-G allele and
atherosclerotic plaque absence is a novel finding. CX3CL1 has
been implicated in atherosclerotic plaque formation initial process
[18,19]. CX3CR1 (CX3CL1 receptor) knockout mice and animal
treated with CX3CR1 inhibitors show reduced atherosclerotic
plaque formation [32,33]. The functional effects of the CX3CL1
rs614230 or rs4151117 are not known. However, these SNPs are
located near a frame shift mutation that may diminish protein
functionality. Our results seem to agree with the reported
atheroprotective effects of CX3CL1 reduced activity.
The CCL5 rs3817655-A and rs2107538-T alleles were found
associated with atherosclerotic plaque presence. The CCL5
rs2107538 polymorphism has been previously associated with
higher plasma concentrations of CCL5 and increased risk of MI in
Korean CAD patients [34] and Han Chinese MI patients [15].
Our results seem to agree with these findings as the T allele
associated with plaque presence in our study is also associated with
MI risk. The CCL5 rs3817655 finding is a novel association that
has not been previously described. This SNP is near to two
mutations that encode for new stop codons and truncated proteins.
Our findings may reflect the functional effect of these mutations
but further studies are required to confirm it.
Carotid Intima Media Thickness
The CRP rs1130864-T allele was found marginally associated
with smaller cIMT and the rs1800947-C allele with greater cIMT.
These results are in the opposite direction that in previous studies.
The CRP rs1130864-T allele was found associated with increased
CRP plasma levels [14], which are considered a marker of
cardiovascular risk [35,36], and have been linked to a faster cIMT
progression in HIV-infected individuals [37]. The CRP
rs1800947-C allele have been previously linked to decreased
CRP plasma levels [15,38], which are known to be atheroprotec-
tive. Although the functional consequences of these SNPs are not
known, both of them are in regulatory regions. The presence of
HIV could interact with the functionality of these genetic variants
explaining the discrepancy between our findings and those
published previously. These findings need to be replicated in
independent cohorts to confirm the direction of the associations.
The IL1RN rs380092-T allele was found associated with
smaller cIMT, although in previous studies has been associated
with increased risk of MI [16,17,39]. The IL1RN rs380092
variant is located approximately 200 bp up-stream of another
variant, rs121913161, which encodes for a new stop codon that
significantly reduces IL1RN plasma levels. IL1RN has been
suggested to be a proatherogenic cytokine [40] and diminished
levels of IL1RN might be atheroprotective [41]. This would agree
with our findings. However, this result needs to be repeated as this
SNP was not found in HWE.
In studies performed by Shrestha et al. on American HIV-
infected patients, an association was found between the RYR3
rs2229116 polymorphism and cIMT [22]. However, we were not
able to replicate this finding. Aside from a false negative result, the
discrepancy could be explained by the methodological differences
in cIMT measures and/or different allele frequencies between
American and Spanish populations.
This study has several limitations. Our cohort has a limited
sample size, although it is very well characterized. High prevalence
of cardiovascular risk traditional factors and the bias observed in
HIV-infected populations should also be considered as a limitation
and a possible source of error in our findings. The lack of an HIV-
negative control group prevented drawing any conclusions about
the contribution of HIV infection to early atherosclerosis.
However, studies have suggested that the biological processes
involved in HIV-related atherosclerosis are different from the ones
observed in non-infected individuals. Moreover, it seems that the
atherosclerotic plaque structure and characteristics are also
different [42]. Finally, carotid ultrasonography measures are
conditioned by its inter and intra-variability.
In summary, in this study we have found modest associations
between genetic variants in several inflammatory genes and
cardiovascular risk markers in an HIV-infected population. They
need to be confirmed in a larger population and functional studies
are needed to elucidate the consequences of these genetic changes.
Nevertheless, our study adds evidence to the association between
inflammatory pathway genetic variants and the atherosclerotic
disease in HIV-infected individuals.
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